Evidence map›Paper›PMID 38003400›Full record

ArticleInternational journal of molecular sciences2023

BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of VEGFR-2 in a Patient-Derived Xenograft Model.

Jean Courcier, Ingrid Leguerney, Baya Benatsou, Sibylle Pochon, Isabelle Tardy, Laurence Albiges, Paul-Henry Cournède, Alexandre De La Taille, Nathalie Lassau, Alexandre Ingels

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. CEUS with VEGFR2-targeted microbubbles for monitoring of early immunotherapy effects in a colorectal cancer model.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jean CourcierDepartment of Urology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), 94000 Créteil, France.
Ingrid LeguerneyBiomaps, UMR1281, INSERM, Centre National de la Recherche Scientifique (CNRS), Commissariat à l'Energie Atomique (CEA), Université Paris Saclay, 94800 Villejuif, France.ORCID 0000-0001-9752-6719
Baya BenatsouBiomaps, UMR1281, INSERM, Centre National de la Recherche Scientifique (CNRS), Commissariat à l'Energie Atomique (CEA), Université Paris Saclay, 94800 Villejuif, France.
Sibylle PochonBracco Suisse SA, 1201 Geneva, Switzerland.
Isabelle TardyBracco Suisse SA, 1201 Geneva, Switzerland.
Laurence AlbigesDepartment of Urological Oncology, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Paul-Henry CournèdeLaboratory of Mathematics and Computer Science (MICS), CentraleSupélec, Université Paris-Saclay, 91190 Gif-Sur-Yvette, France.ORCID 0000-0001-7679-6197
Alexandre De La TailleDepartment of Urology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), 94000 Créteil, France.
Nathalie LassauBiomaps, UMR1281, INSERM, Centre National de la Recherche Scientifique (CNRS), Commissariat à l'Energie Atomique (CEA), Université Paris Saclay, 94800 Villejuif, France.
Alexandre IngelsDepartment of Urology, Henri Mondor Hospital, University of Paris Est Créteil (UPEC), 94000 Créteil, France.ORCID 0000-0002-0043-6520
Centre National de la Recherche Scientifique · FRBracco (Switzerland) · CHInstitut Gustave Roussy · FRUniversité Paris-Est Créteil · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Standard imaging cannot reliably predict the nature of renal tumors. Among malignant renal tumors, clear cell renal cell carcinoma (ccRCC) is the most common histological subtype, in which the vascular endothelial growth factor 2 (VEGFR-2) is highly expressed in the vascular endothelium. BR55, a contrast agent for ultrasound imaging, consists of gas-core lipid microbubbles that specifically target and bind to the extracellular portion of the VEGFR-2. The specific information provided by ultrasound molecular imaging (USMI) using BR55 was compared with the vascular tumor expression of the VEGFR-2 by immunohistochemical (IHC) staining in a preclinical model of ccRCC. Patients' ccRCCs were orthotopically grafted onto Nod-Scid-Gamma (NSG) mice to generate patient-derived xenografts (PdX). Mice were divided into four groups to receive either vehicle or axitinib an amount of 2, 7.5 or 15 mg/kg twice daily. Perfusion parameters and the BR55 ultrasound contrast signal on PdX renal tumors were analyzed at D0, D1, D3, D7 and D11, and compared with IHC staining for the VEGFR-2 and CD34. Significant Pearson correlation coefficients were observed between the area under the curve (AUC) and the CD34 (0.84,

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAnimalsContrast MediaHeterograftsHumansMiceMolecular ImagingUltrasonographyVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Contrast MediaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2axitinibBR55molecular imagingpatient’s derived xenograftrenal cell carcinomasultrasoundVEGFR-2

Identifiers

PMID38003400
PMCPMC10671137
OpenAlexW4388636006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.